Estimands for Randomized Discontinuation Designs in Oncology
Pharmaceutical Statistics · 2026-11 · 25 (6)
DOI: 10.1002/pst.70141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 01.11.2026. Verfasst von Ayon Mukherjee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences Institute, Newcastle University, Newcastle, UK. Hauptthemen laut MEDLINE: Research Design, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Stomach Neoplasms. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
The Randomized Discontinuation Design (RDD) is a two‐stage adaptive enrichment design that is uniquely suited to answer causal questions about the benefit of continuing treatment in patients who have already demonstrated response to an induction therapy. The estimand framework from the International Council for Harmonisation (ICH) E9(R1) addendum provides the necessary language to precisely define this scientific question. A major challenge in formulating estimands for RDD oncology trials is that the target population for the primary scientific question is itself defined by a post‐treatment biological outcome in Stage 1, which makes it difficult to separate the process of selecting eligible participants from the causal inference problem in Stage 2. In this paper, we address this challenge using the Phase III JAVELIN Gastric 100 trial as an example. We argue that the “conventional” estimand can be formulated as an estimand targeting the response‐defined subgroup of participants with evidence of response to the induction therapy in Stage 1, and we clarify the precise sense in which this subgroup is, and is not, related to the concept of a principal stratum. We also formulate a “full‐path” estimand—capturing the patients' entire two‐stage treatment journey—and connect it to the dynamic treatment regime literature. We also provide Directed Acyclic Graphs (DAGs) for the two estimands to clarify their respective causal structures. This paper aims to strengthen the dialogue among clinical research stakeholders tasked with the design and analysis of RDD trials and support more efficient regulatory decision‐making. Trial Registration: ClinicalTrials.gov identifier: NCT02625610
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Population Health Sciences Institute, Newcastle University, Newcastle, UK.
- Quantitative Sciences, Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
- Biostatistics, Genentech Inc., South San Francisco, California, USA.
ORCID-Profile: Ayon Mukherjee, Oleksandr Sverdlov, Yu Deng
Zitieren
APA
Mukherjee, A., Sverdlov, O., & Deng, Y. (2026). Estimands for Randomized Discontinuation Designs in Oncology. Pharmaceutical Statistics, 25(6). https://doi.org/10.1002/pst.70141
Vancouver
Mukherjee A, Sverdlov O, Deng Y. Estimands for Randomized Discontinuation Designs in Oncology. Pharmaceutical Statistics. 2026;25(6). doi:10.1002/pst.70141
BibTeX
@article{Mukherjee2026,
author = {Mukherjee, Ayon and Sverdlov, Oleksandr and Deng, Yu},
title = {Estimands for Randomized Discontinuation Designs in Oncology},
journal = {Pharmaceutical Statistics},
year = {2026},
volume = {25},
number = {6},
doi = {10.1002/pst.70141}
}
EUVIMED